UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways

Table 1 Data of 447 melanoma patients from TCGA

Characteristics	N	Percentages	Characteristics	N	Percentages
T			Clark level
Ti	7	1.75	I/II/III	98	31.72
T1	41	10.28	IV/V	211	68.29
T2	76	19.05	Ulceration
T3	89	22.31	No	144	47.37
T4	144	36.09	Yes	160	52.63
N			Cancer status
N0	222	59.04	Tumor free	210	49.64
N1	73	19.41	With tumor	213	50.35
N2	49	13.03	New tumor event
M			No	110	25.23
M0	402	95.04	Yes	326	74.77
M1	21	4.96	Race
Stage			Asian	11	2.51
Stage0	6	1.49	White	427	97.49
Stage1	76	18.81	Age
Stage2	133	32.92	< 60	237	53.02
Stage3	169	41.83	≥ 60	210	46.98
Stage4	20	4.95	Site
–	–	–	Extremities	191	49.35
–	–	–	Head and neck	32	8.27
–	–	–	Trunk	164	42.38

Patient characteristics included TNM stage, clinical stage, Clark level, ulceration, cancer status, new tumor event, race, age and site were identified

ISSN: 1475-2867